Weight-Loss Injections Linked to Increased Fertility and 'Ozempic Babies'

Experts highlight the impact of GLP-1 receptor agonists on fertility, urging careful medical guidance for users.

GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, are prescription drugs used for weight loss and Type 2 diabetes management.
Weight loss of just 5-10% can normalize ovulation and improve fertility, particularly in women with obesity, according to medical experts.
The medications may benefit women with conditions like polycystic ovary syndrome (PCOS) or diabetes who face challenges with conception.
Experts caution that these drugs can interfere with hormonal contraceptives and recommend effective birth control for women not seeking pregnancy.
The European Medicines Agency advises discontinuing these medications at least two months before pregnancy due to potential risks to fetal development.